

Clinically Important Drug Interactions Potentially Involving of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

Therapeutic Drug Monitoring

29, 687-710

DOI: [10.1097/ftd.0b013e31815c16f5](https://doi.org/10.1097/ftd.0b013e31815c16f5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 871, 130-134.	1.2	25
2	Pharmacokinetics for the prescriber. <i>Medicine</i> , 2008, 36, 350-354.	0.2	4
3	Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. <i>Xenobiotica</i> , 2008, 38, 802-832.	0.5	499
4	Psoriasis and HIV Infection. <i>Actas Dermo-sifiliográficas</i> , 2008, 99, 753-763.	0.2	5
5	Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. <i>Virology Journal</i> , 2008, 5, 111.	1.4	10
6	Psoriasis e infección por el virus de la inmunodeficiencia humana. <i>Actas Dermo-sifiliográficas</i> , 2008, 99, 753-763.	0.2	18
7	Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1 in vitro and implications for drug-drug interactions. <i>Xenobiotica</i> , 2008, 38, 1203-1218.	0.5	32
9	Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4. <i>Current Drug Metabolism</i> , 2008, 9, 310-322.	0.7	550
10	Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4. <i>Current Pharmaceutical Design</i> , 2008, 14, 990-1000.	0.9	44
11	Pharmacological enhancement of protease inhibitors with ritonavir: an update. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 533-545.	1.3	10
12	Iatrogenic Cushing Syndrome after Epidural Triamcinolone Injections in an HIV Type 1 Infected Patient Receiving Therapy with Ritonavir-Lopinavir. <i>Clinical Infectious Diseases</i> , 2008, 47, e97-e99.	2.9	43
13	Antiretroviral therapy and anaesthesia. <i>Southern African Journal of Anaesthesia and Analgesia</i> , 2008, 14, 31-38.	0.1	5
14	Clinical Drugs that Interact with St. Johns Wort and mplication in Drug Development. <i>Current Pharmaceutical Design</i> , 2008, 14, 1723-1742.	0.9	91
15	Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 861-868.	0.7	72
16	Current World Literature. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 681-689.	1.5	0
17	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , 2008, 43, 150-153.	0.4	0
18	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , 2008, 43, 1024-1029.	0.4	1
19	A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1970-1977.	1.7	220

#	ARTICLE	IF	CITATIONS
20	Substrate Specificity, Inhibitors and Regulation of Human Cytochrome P450 2D6 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 2661-2805.	1.2	64
21	Concomitant Medication Use Can Confound Interpretation of the Combined Dexamethasone-Corticotropin Releasing Hormone Test in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4851-4859.	1.8	67
22	Opioid Metabolism. <i>Mayo Clinic Proceedings</i> , 2009, 84, 613-624.	1.4	537
23	Pharmacogenomics of CYP3A: considerations for HIV treatment. <i>Pharmacogenomics</i> , 2009, 10, 1323-1339.	0.6	46
24	Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. <i>Xenobiotica</i> , 2009, 39, 749-756.	0.5	8
25	The Biochemistry of Drug Metabolism – An Introduction. <i>Chemistry and Biodiversity</i> , 2009, 6, 1477-1660.	1.0	29
26	Irreversible CYP3A Inhibition Accompanied by Plasma Protein Binding Displacement: A Comparative Analysis in Subjects With Normal and Impaired Liver Function. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 319-326.	2.3	29
27	Verapamil for Cluster Headache. <i>Clinical Pharmacology and Possible Mode of Action. Headache</i> , 2009, 49, 117-125.	1.8	63
28	Classification models for CYP450 3A4 inhibitors and non-inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 2354-2360.	2.6	23
29	Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC ₅₀ shift approach facilitates inactivated assay design. <i>Xenobiotica</i> , 2009, 39, 99-112.	0.5	80
30	Application of mechanism-based CYP inhibition for predicting drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 579-605.	1.5	29
31	Chapter 26 Mechanism-Based Inhibition of CYP3A4 and Other Cytochromes P450. <i>Annual Reports in Medicinal Chemistry</i> , 2009, 44, 535-553.	0.5	4
32	The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1355-1370.	1.7	279
33	Interactions Between Herbal Medicines and Prescribed Drugs. <i>Drugs</i> , 2009, 69, 1777-1798.	4.9	513
34	In vitro evaluation of differences in phase 1 metabolism of ketamine and other analgesics among humans, horses, and dogs. <i>American Journal of Veterinary Research</i> , 2009, 70, 777-786.	0.3	28
35	Immunotherapy in Elderly Transplant Recipients. <i>Drugs and Aging</i> , 2009, 26, 715-737.	1.3	68
36	Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1189-1211.	1.5	13
37	Opioid Metabolism. <i>Mayo Clinic Proceedings</i> , 2009, 84, 613-624.	1.4	354

#	ARTICLE	IF	CITATIONS
38	Serum Concentrations of Antidepressant Drugs in a Naturalistic Setting: Compilation Based on a Large Therapeutic Drug Monitoring Database. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 42-56.	1.0	121
39	Antiepileptic Drug Interactions - Principles and Clinical Implications. <i>Current Neuropharmacology</i> , 2010, 8, 254-267.	1.4	275
40	Optimizing Antibiotic Use in the Intensive Care Unit. <i>Clinical Pulmonary Medicine</i> , 2010, 17, 162-169.	0.3	1
41	Common drug interactions leading to adverse drug events in the intensive care unit: Management and pharmacokinetic considerations. <i>Critical Care Medicine</i> , 2010, 38, S126-S135.	0.4	43
42	Vincristine and Intestinal Pseudo-obstruction in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, e126-e130.	0.3	18
43	Species Differences in Mechanism-Based Inactivation of CYP3A in Humans, Rats and Mice. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 93-100.	1.1	19
44	Metabolic interactions with piperazine-based "party pill"™ drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 877-882.	1.2	0
45	Pharmacogenetics and forensic toxicology. <i>Forensic Science International</i> , 2010, 203, 53-62.	1.3	56
46	The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. <i>Thrombosis and Haemostasis</i> , 2010, 103, 920-925.	1.8	80
47	Rifampin Combination Therapy for Nonmycobacterial Infections. <i>Clinical Microbiology Reviews</i> , 2010, 23, 14-34.	5.7	199
48	Urine Drug Testing of Chronic Pain Patients. II. Prevalence Patterns of Prescription Opiates and Metabolites. <i>Journal of Analytical Toxicology</i> , 2010, 34, 32-38.	1.7	39
49	The Effects of a Short Course of Antibiotics on Alvimopan and Metabolite Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 338-349.	1.0	5
50	Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1857-1864.	1.7	116
51	Toxicokinetic Interaction Between Quetiapine and Antiretroviral Therapy Following Quetiapine Overdose. <i>Drug Metabolism Letters</i> , 2010, 4, 7-8.	0.5	14
52	Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations. <i>Current Medicinal Chemistry</i> , 2010, 17, 1635-1678.	1.2	76
53	Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1732-1756.	1.0	26
54	Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. <i>Drug Metabolism Reviews</i> , 2010, 42, 268-354.	1.5	220
55	Herb-drug pharmacokinetic interactions reviewed. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1515-1538.	1.5	76

#	ARTICLE	IF	CITATIONS
57	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1215-1230.	1.5	11
58	Histologic Patterns of Hepatotoxic Injury*. , 2010, , 141-173.		6
59	QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 699-712.	1.0	23
60	Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. <i>Journal of Psychopharmacology</i> , 2010, 24, 297-307.	2.0	43
61	Issues in drug metabolism of major antihypertensive drugs: β -blockers, calcium channel antagonists and angiotensin receptor blockers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 199-211.	1.5	22
62	Implications of Opioid Analgesia for Medically Complicated Patients. <i>Drugs and Aging</i> , 2010, 27, 417-433.	1.3	85
63	Supportive Cancer Care with Chinese Medicine. , 2010, , .		15
64	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 999-1014.	0.6	4
65	Concurrent medical conditions should be considered when prescribing opioid analgesics. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 9-12.	0.3	0
66	Comparative Metabolism of Cinobufagin in Liver Microsomes from Mouse, Rat, Dog, Minipig, Monkey, and Human. <i>Drug Metabolism and Disposition</i> , 2011, 39, 675-682.	1.7	58
67	Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. <i>Clinics</i> , 2011, 66, 9-15.	0.6	81
68	Drug Interactions in Infectious Diseases. , 2011, , .		11
69	The Medicinal Chemistry of Tuberculosis Chemotherapy. <i>Topics in Medicinal Chemistry</i> , 2011, , 47-124.	0.4	17
70	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 609-622.	1.5	15
71	Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 78, 166-172.	2.0	70
72	Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 386-396.	1.5	39
73	Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine. <i>Current Drug Metabolism</i> , 2011, 12, 989-996.	0.7	142
74	Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1892-1901.	1.9	39

#	ARTICLE	IF	CITATIONS
75	New Uses for Old Drugs: Pharmacophore-Based Screening for the Discovery of Glycoprotein Inhibitors. <i>Chemical Biology and Drug Design</i> , 2011, 78, 57-72.	1.5	56
76	Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 579-586.	2.3	50
77	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. <i>Blood</i> , 2011, 117, e75-e87.	0.6	202
79	Electroanalysis of Cytochrome P450 3A4 Catalytic Properties with Nanostructured Electrodes: The Influence of Vitamin B Group on Diclofenac Metabolism. <i>BioNanoScience</i> , 2011, 1, 46-52.	1.5	17
80	Inhibitory Effects of <i>Phyllanthus amarus</i> and Its Major Lignans on Human Microsomal Cytochrome P450 Activities: Evidence for CYP3A4 Mechanism-Based Inhibition. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 154-161.	1.1	38
81	Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 103-113.	1.5	28
82	Biological effects of <i>Byrsocarpus coccineus</i> in vitro. <i>Pharmaceutical Biology</i> , 2011, 49, 152-160.	1.3	7
83	Comparison of the Inhibitory Profiles of Itraconazole and Cimetidine in Cytochrome P450 3A4 Genetic Variants. <i>Drug Metabolism and Disposition</i> , 2011, 39, 724-728.	1.7	24
84	Pharmacokinetics of ropivacaine in patients with chronic renal failure. <i>British Journal of Anaesthesia</i> , 2011, 106, 512-521.	1.5	22
85	Cushing's syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops. <i>Aids</i> , 2011, 25, 1337-1339.	1.0	18
86	Traditional Medicines, HIV, and Related Infections. <i>Advances in Dental Research</i> , 2011, 23, 159-164.	3.6	6
87	Cytochrome P450-mediated cardiovascular drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1065-1082.	1.5	26
88	Regulation of Biotransformation Systems and ABC Transporters by Benznidazole in HepG2 Cells: Involvement of Pregnane X-Receptor. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1951.	1.3	20
89	Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content. <i>Xenobiotica</i> , 2012, 42, 1163-1169.	0.5	14
90	Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction. <i>Current Medical Research and Opinion</i> , 2012, 28, 551-557.	0.9	7
91	Attempted Suicide by Self-Immolation is a Powerful Predictive Variable for Survival of Burn Injuries. <i>Journal of Burn Care and Research</i> , 2012, 33, 642-648.	0.2	27
92	Disposition Pathways and Pharmacokinetics of Herbal Medicines in Humans. <i>Current Medicinal Chemistry</i> , 2012, 17, 4072-4113.	1.2	41
94	Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro. <i>Drug Metabolism and Disposition</i> , 2012, 40, 655-661.	1.7	75

#	ARTICLE	IF	CITATIONS
95	Two cases of paralytic ileus in onco-hematologic patients. <i>Mental Illness</i> , 2012, 4, 3.	0.8	3
96	Reliable High-throughput Method for Inhibition Assay of 8 Cytochrome P450 Isoforms Using Cocktail of Probe Substrates and Stable Isotope-labeled Internal Standards. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 520-529.	1.1	50
98	Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System. <i>Clinical Drug Investigation</i> , 2012, 32, 583-592.	1.1	22
99	The Clinical Implications of Cytochrome P450 Interactions With Opioids and Strategies for Pain Management. <i>Journal of Pain and Symptom Management</i> , 2012, 44, S15-S22.	0.6	17
100	Opioid Therapies and Cytochrome P450 Interactions. <i>Journal of Pain and Symptom Management</i> , 2012, 44, S4-S14.	0.6	60
101	Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7605-7609.	1.0	5
102	Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. <i>Heart</i> , 2012, 98, 1366-1372.	1.2	34
103	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. <i>British Journal of Pharmacology</i> , 2012, 165, 2787-2798.	2.7	74
104	Statistical Methods for Analysis of Time-Dependent Inhibition of Cytochrome P450 Enzymes. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2289-2296.	1.7	27
105	Drug Interaction Studies With CYP3A Substrates: How Much Inhibitor Pre-exposure Is Needed?. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 83-84.	0.8	5
106	Drug Interactions with Herbal Medicines. <i>Clinical Pharmacokinetics</i> , 2012, 51, 77-104.	1.6	116
107	Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. <i>Contraception</i> , 2012, 86, 337-344.	0.8	27
108	<i>In vitro</i> Inhibition of CYP3A4 by the Multiherbal Commercial Product Sambucus Force and its Main Constituents <i>Echinacea purpurea</i> and <i>Sambucus nigra</i> . <i>Phytotherapy Research</i> , 2012, 26, 1606-1613.	2.8	10
109	Modeling Chemical Interaction Profiles: I. Spectral Data-Activity Relationship and Structure-Activity Relationship Models for Inhibitors and Non-inhibitors of Cytochrome P450 CYP3A4 and CYP2D6 Isozymes. <i>Molecules</i> , 2012, 17, 3383-3406.	1.7	13
110	Methodologies used to identify and characterize interactions among antiepileptic drugs. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 281-292.	1.3	24
112	Host factors affecting antiepileptic drug delivery—Pharmacokinetic variability. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 896-910.	6.6	92
113	Concentration effect relationship of CYP3A inhibition by ritonavir in humans. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1795-1800.	0.8	38
114	Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 27.	1.0	21

#	ARTICLE	IF	CITATIONS
115	The Effect of Ticagrelor on the Metabolism of Midazolam in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2013, 35, 1025-1037.	1.1	15
116	Drug-Vitamin D Interactions. <i>Nutrition in Clinical Practice</i> , 2013, 28, 194-208.	1.1	93
117	Prescription Opioids. II. Metabolism and Excretion Patterns of Hydrocodone in Urine Following Controlled Single-Dose Administration. <i>Journal of Analytical Toxicology</i> , 2013, 37, 486-494.	1.7	23
119	Drug-Induced Liver Injury: The Role of Drug Metabolism and Transport. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 463-474.	1.0	126
120	Amlodipine not a significant contributor to clopidogrel non-response?. <i>Heart</i> , 2013, 99, 437-439.	1.2	3
121	Managing the Risks of Cardiac Therapy in Cancer Patients. <i>Seminars in Oncology</i> , 2013, 40, 210-217.	0.8	3
122	Psychophysiological stress: a significant parameter in drug pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1317-1334.	1.5	37
123	Fluoxetine Inhibition of CYP3A4 Potentiating Adrenal Suppression and Peptic Ulcer Disease from Intra-Articular Triamcinolone Injections. <i>Pain Medicine</i> , 2013, 14, 952-953.	0.9	3
124	Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity. <i>Clinical Lung Cancer</i> , 2013, 14, 502-507.	1.1	50
125	Left ventricular hypertrabeculation/noncompaction coincidentally found in sporadic inclusion body myositis. <i>International Journal of Cardiology</i> , 2013, 168, 610-612.	0.8	5
126	From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. <i>International Journal of Pharmaceutics</i> , 2013, 452, 14-35.	2.6	63
127	Thiazolidinedione usage is associated with decreased response to clopidogrel in DM patients. <i>International Journal of Cardiology</i> , 2013, 168, 608-610.	0.8	2
128	Resistance to high-maintenance dose of prasugrel treated by ticagrelor: A case report. <i>Platelets</i> , 2013, 24, 239-241.	1.1	13
129	Drug-Drug Interaction: Enzyme Inhibition. , 2013, , 989-1004.		1
130	Opioids for Chronic Pain: New Evidence, New Strategies, Safe Prescribing. <i>American Journal of Medicine</i> , 2013, 126, S3-S11.	0.6	73
131	Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. <i>Journal of Drug Assessment</i> , 2013, 2, 30-39.	1.1	34
132	Stroke Pharmacogenetics. , 2013, , 223-297.		0
133	Prescription Opioids. I. Metabolism and Excretion Patterns of Oxycodone in Urine Following Controlled Single Dose Administration. <i>Journal of Analytical Toxicology</i> , 2013, 37, 255-264.	1.7	25

#	ARTICLE	IF	CITATIONS
134	Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir. <i>International Journal of STD and AIDS</i> , 2013, 24, 748-752.	0.5	32
135	The role of mineralocorticoid receptor function in treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2013, 27, 1169-1179.	2.0	57
136	Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: a randomised, controlled trial. <i>Heart</i> , 2013, 99, 468-473.	1.2	16
137	CYP3A4 Genetic Status May Be Associated With Increased Vulnerability to the Inhibitory Effect of Calcium-Channel Blockers on Clopidogrel. <i>Circulation Journal</i> , 2013, 77, 1289-1296.	0.7	12
138	A Simple Method to Evaluate Reactivity of Acylglucuronides Optimized for Early Stage Drug Discovery. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 1509-1513.	0.6	27
139	Options for treating postherpetic neuralgia in the medically complicated patient. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 329.	0.9	16
140	Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. <i>International Journal of COPD</i> , 2014, 10, 15.	0.9	10
141	Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1035-1042.	1.1	25
142	Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. <i>Epileptic Disorders</i> , 2014, 16, 409-431.	0.7	212
143	Artemisinin-Based Combination Therapies Are Efficacious and Safe for Treatment of Uncomplicated Malaria in HIV-Infected Ugandan Children. <i>Clinical Infectious Diseases</i> , 2014, 59, 446-453.	2.9	17
144	Inhibitory effects of dioscin on cytochrome P450 enzymes. <i>RSC Advances</i> , 2014, 4, 54026-54031.	1.7	6
145	Chronic Idiopathic Nausea. <i>Pediatric Annals</i> , 2014, 43, e89-94.	0.3	1
146	Effects of Ketoconazole on the Pharmacokinetic Properties of CG100649, A Novel NSAID: A Randomized, Open-Label Crossover Study in Healthy Korean Male Volunteers. <i>Clinical Therapeutics</i> , 2014, 36, 115-125.	1.1	5
147	Urinary Diazepam Metabolite Distribution in a Chronic Pain Population. <i>Journal of Analytical Toxicology</i> , 2014, 38, 135-142.	1.7	18
148	Deoxyschizandrin, a Naturally Occurring Lignan, Is a Specific Probe Substrate of Human Cytochrome P450 3A. <i>Drug Metabolism and Disposition</i> , 2014, 42, 94-104.	1.7	20
149	Optimization in Drug Discovery. <i>Methods in Pharmacology and Toxicology</i> , 2014, , .	0.1	23
150	The Association Between Drugs Frequently Used by the Elderly and Vitamin D Blood Levels: A Review of Observational and Experimental Studies. <i>Drugs and Aging</i> , 2014, 31, 111-123.	1.3	7
151	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	1.3	31

#	ARTICLE	IF	CITATIONS
152	Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on humanized animal models. <i>Drug Metabolism Reviews</i> , 2014, 46, 475-493.	1.5	28
153	Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: an <i>In Vitro</i> Evaluation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1294-1301.	1.4	24
154	Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data. <i>AAPS Journal</i> , 2014, 16, 1309-1320.	2.2	31
155	Drug-drug interactions in HIV positive cancer patients. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 665-677.	2.5	15
156	Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. <i>Leukemia Research</i> , 2014, 38, 764-772.	0.4	37
157	Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 551-582.	1.0	16
158	New antiviral agents for the treatment of hepatitis C: ABT-450. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 711-716.	0.9	27
159	Consequences of psychophysiological stress on cytochrome P450-catalyzed drug metabolism. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 45, 149-167.	2.9	36
160	Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2555.	2.0	11
162	Human hepatocyte assessment of imatinib drug-drug interactions complexities in clinical translation. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1097-1108.	1.1	7
163	A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. <i>Lipids in Health and Disease</i> , 2015, 14, 131.	1.2	11
164	Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 708-717.	1.0	43
165	Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450 3A in drug-drug interaction studies. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 342-350.	1.1	83
166	Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. <i>Clinical Interventions in Aging</i> , 2015, 10, 1457.	1.3	64
167	Interactions between CYP3A4 and Dietary Polyphenols. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 1-15.	1.9	126
168	Cytochrome P450 Enzymes and Electrochemistry: Crosstalk with Electrodes as Redox Partners and Electron Sources. <i>Advances in Experimental Medicine and Biology</i> , 2015, 851, 229-246.	0.8	7
169	Aortic Atherosclerosis as an Embolic Source. , 2015, , 1-64.		0
170	Applicability of second-generation upcyte human hepatocytes for use in CYP inhibition and induction studies. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00161.	1.1	24

#	ARTICLE	IF	CITATIONS
171	eCounterscreening: Using QSAR Predictions to Prioritize Testing for Off-Target Activities and Setting the Balance between Benefit and Risk. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 231-238.	2.5	12
172	Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 437-449.	1.5	24
173	Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. <i>Hepatology Research</i> , 2015, 45, E156-60.	1.8	5
174	Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 617-624.	0.9	23
175	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1259-1272.	1.6	44
176	Metabolic activation of hepatotoxic drug (benzbromarone) induced mitochondrial membrane permeability transition. <i>Toxicology and Applied Pharmacology</i> , 2015, 288, 12-18.	1.3	18
177	Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 547-558.	1.4	23
178	Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. <i>Bioanalysis</i> , 2015, 7, 481-495.	0.6	21
179	Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area. <i>Liver Transplantation</i> , 2015, 21, 353-361.	1.3	33
180	Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 119-120.	0.7	15
181	Pain management in cryoglobulinaemic syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 77-89.	1.4	6
182	Electrocatalytic cycle of P450 cytochromes: the protective and stimulating roles of antioxidants. <i>RSC Advances</i> , 2015, 5, 71306-71313.	1.7	16
183	Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events. <i>PLoS ONE</i> , 2016, 11, e0163224.	1.1	6
184	Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers. <i>Medicine (United States)</i> , 2016, 95, e2487.	0.4	34
185	Phyto-anesthetics: A mini-review on herb-anesthesia drug interactions. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1885-1890.	2.5	16
186	QSAR Modeling and Prediction of Drug-Drug Interactions. <i>Molecular Pharmaceutics</i> , 2016, 13, 545-556.	2.3	65
187	Vitamin D deficiency as adverse drug reaction? A cross-sectional study in Dutch geriatric outpatients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 605-614.	0.8	15
188	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 711-717.	0.8	23

#	ARTICLE	IF	CITATIONS
189	A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 719-723.	0.8	19
190	Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. <i>Drug Metabolism Reviews</i> , 2016, 48, 88-112.	1.5	119
191	Single concentration loss of activity assay provides an improved assessment of drug-drug interaction risk compared to IC50-shift. <i>Xenobiotica</i> , 2016, 46, 953-966.	0.5	6
192	Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. <i>Clinical Pharmacokinetics</i> , 2016, 55, 197-208.	1.6	65
193	Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 2 of 5 series. <i>Food and Chemical Toxicology</i> , 2017, 107, 472-501.	1.8	96
194	Drug Interactions in Neurocritical Care. <i>Neurocritical Care</i> , 2017, 27, 287-296.	1.2	4
195	Transport-Glucuronidation Classification System and PBPK Modeling: New Approach To Predict the Impact of Transporters on Disposition of Glucuronides. <i>Molecular Pharmaceutics</i> , 2017, 14, 2884-2898.	2.3	8
196	Mechanisms and Consequences of Drug-Drug Interactions. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 118-124.	0.8	18
197	Cardio-Oncology. , 2017, , .		1
198	Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia. , 2017, , 175-214.		0
199	Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies. <i>Pharmaceutical Research</i> , 2017, 34, 1925-1933.	1.7	7
200	Life-threatening drug interactions: what the physician needs to know. <i>Internal Medicine Journal</i> , 2017, 47, 501-512.	0.5	36
201	Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?. <i>Nutrition in Clinical Practice</i> , 2017, 32, 607-627.	1.1	29
202	Atorvastatin-Diltiazem Combination Induced Rhabdomyolysis Leading to Diagnosis of Hypothyroidism. <i>Case Reports in Medicine</i> , 2017, 2017, 1-4.	0.3	5
203	Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5053-5064.	1.0	22
204	Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. <i>Journal of Experimental Pharmacology</i> , 2017, Volume 9, 47-57.	1.5	8
205	IN VIVO EFFECT OF RUTA CHALEPENSIS EXTRACT ON HEPATIC CYTOCHROME 3A1 IN RATS. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2017, 14, 62-68.	0.3	3
206	Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A. <i>Molecular Pharmaceutics</i> , 2018, 15, 1979-1995.	2.3	26

#	ARTICLE	IF	CITATIONS
207	A study on the genetic polymorphisms of <i>CYP3A5</i> among the Orang Asli in Malaysia using a next generation sequencing platform. <i>Annals of Human Biology</i> , 2018, 45, 166-169.	0.4	3
208	Corticosteroid and Cortisol Serum Levels Following Intra-articular Triamcinolone Acetonide Lumbar Facet Joint Injections. <i>Pain Practice</i> , 2018, 18, 864-870.	0.9	15
209	CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 51-54.	0.3	15
210	Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 111, 465-481.	1.9	22
211	Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 501-509.	1.1	15
212	Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. <i>Frontiers in Neurology</i> , 2018, 9, 1067.	1.1	60
213	Assessing Herb-Drug Interactions of Herbal Products With Therapeutic Agents for Metabolic Diseases: Analytical and Regulatory Perspectives. <i>Studies in Natural Products Chemistry</i> , 2018, 59, 283-322.	0.8	12
214	Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Toxicology</i> , 2018, 18, 482-491.	1.1	7
215	Interpretation the Hepatotoxicity Based on Pharmacokinetics Investigated Through Oral Administrated Different Extraction Parts of <i>Polygonum multiflorum</i> on Rats. <i>Frontiers in Pharmacology</i> , 2018, 9, 505.	1.6	32
216	TSH ratio as a novel diagnostic method for Cushing's syndrome. <i>Endocrine Journal</i> , 2018, 65, 841-848.	0.7	7
217	No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2475-2483.	2.0	8
218	Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 229-236.	0.6	8
219	Use of 4β -Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 831-840.	2.3	21
220	Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 732-742.	1.7	6
221	Systemic Absorption and Side Effects of Locally Injected Glucocorticoids. <i>PM and R</i> , 2019, 11, 409-419.	0.9	71
222	Two Approaches for Evaluating the Effects of Galangin on the Activities and mRNA Expression of Seven CYP450. <i>Molecules</i> , 2019, 24, 1171.	1.7	20
223	Members of the same pharmacological family are not alike: Different opioids, different consequences, hope for the opioid crisis?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 428-449.	2.5	21
224	Drug interactions and creatinine levels are associated with QTc prolongation in intensive care units: a prospective, observational study. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .	0.3	4

#	ARTICLE	IF	CITATIONS
225	Pharmacogenomic Testing for Postoperative Pain Optimization Before Total Joint Arthroplasty. <i>JBJS Reviews</i> , 2019, 7, e2-e2.	0.8	3
226	A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 389-408.	0.6	14
227	Post-transplant diabetes mellitus in patients with solid organ transplants. <i>Nature Reviews Endocrinology</i> , 2019, 15, 172-188.	4.3	154
228	Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2019, 119, 264-273.	1.8	2
229	Verapamil as a culprit of palbociclib toxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 743-746.	0.5	8
230	Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. , 2020, 206, 107449.		21
231	In vitro characterization and in vitro to in vivo predictions of drug-drug interactions. , 2020, , 273-309.		0
232	Parameters and Strategies to Overcome Barriers to Systemic Delivery. <i>Healthy Ageing and Longevity</i> , 2020, , 447-475.	0.2	1
233	The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1113-1120.	1.7	5
234	Clopidogrel drug interactions: a review of the evidence and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1079-1096.	1.5	8
235	Systemic Delivery Technologies in Anti-Aging Medicine: Methods and Applications. <i>Healthy Ageing and Longevity</i> , 2020, , .	0.2	2
236	Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles. <i>Drug Metabolism and Disposition</i> , 2020, 48, 508-514.	1.7	5
237	<i>Centella asiatica</i> Water Extract Shows Low Potential for Cytochrome P450-Mediated Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1053-1063.	1.7	4
238	A Drug-Drug Interaction Study to Evaluate the Effect of TAS303 on CYP3A Activity in the Small Intestine and Liver. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 702-710.	1.0	2
239	Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. <i>Pharmacotherapy</i> , 2020, 40, 274-290.	1.2	6
240	Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 579-587.	0.8	14
241	Pharmacogenomics of Antiretroviral Drug Metabolism and Transport. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 565-585.	4.2	4
242	Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 319-327.	1.0	3

#	ARTICLE	IF	CITATIONS
243	Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. <i>Investigational New Drugs</i> , 2021, 39, 272-277.	1.2	12
244	The Exploration of Novel Pharmacophore Characteristics and Multidirectional Elucidation of Structure-Activity Relationship and Mechanism of Sesquiterpene Pyridine Alkaloids from <i>Tripterygium</i> Based on Computational Approaches. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-14.	0.5	2
245	Cytochrome P450 Enzyme Inhibition and Herb-Drug Interaction Potential of Medicinal Plant Extracts Used for Management of Diabetes in Nigeria. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 437-450.	0.6	5
246	Oleuropein-Induced Acceleration of Cytochrome P450 Catalyzed Drug Metabolism: Central Role for Nuclear Receptor Peroxisome Proliferator-Activated Receptor α . <i>Drug Metabolism and Disposition</i> , 2021, 49, 833-843.	1.7	11
247	Immunodeficiency-associated Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 547-559.	1.0	7
248	A Literature Review of the Potential Impact of Medication on Vitamin D Status. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 3357-3381.	1.2	19
249	Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3661-3673.	2.0	4
250	Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing?. <i>Journal of Cystic Fibrosis</i> , 2021, 20, e63-e66.	0.3	7
251	Herb-drug interactions and toxicity: Underscoring potential mechanisms and forecasting clinically relevant interactions induced by common phytoconstituents via data mining and computational approaches. <i>Food and Chemical Toxicology</i> , 2021, 156, 112432.	1.8	10
252	Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials. <i>Cephalalgia Reports</i> , 2021, 4, 251581632110373.	0.2	1
253	Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers. <i>Current Therapeutic Research</i> , 2021, 94, 100619.	0.5	0
254	Introduction to Drug-Drug Interactions. , 2011, , 1-10.		6
255	Third World Diseases. <i>Topics in Medicinal Chemistry</i> , 2011, , .	0.4	2
256	Toxicology, Safety and Herb-drug Interactions in Cancer Therapy. , 2010, , 293-340.		1
257	Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy. , 2012, , 1433-1452.e10.		2
259	Metabolic interactions with piperazine-based 'party pill' drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 877-882.	1.2	30
260	Polypharmacy in Alzheimer's disease patients in Brazil: Guidance for pharmaceutical assistance. <i>F1000Research</i> , 0, 6, 2068.	0.8	1
261	Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System. <i>Clinical Drug Investigation</i> , 2012, 32, 583-592.	1.1	18

#	ARTICLE	IF	CITATIONS
262	Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies. <i>Current Drug Metabolism</i> , 2019, 20, 114-123.	0.7	6
263	CYP Inhibition-Mediated Drug-Drug Interactions. <i>Current Enzyme Inhibition</i> , 2010, 6, 130-145.	0.3	2
264	Pharmacokinetic drug interactions in liver disease: An update. <i>World Journal of Gastroenterology</i> , 2016, 22, 1260.	1.4	62
265	Serotonin Reuptake Inhibitor Treatment of Obsessive-Compulsive Symptoms in Clozapine-Medicated Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e1362-e1364.	1.1	6
266	Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area : cardiovascular topics. <i>Cardiovascular Journal of Africa</i> , 2013, 24, 19-23.	0.2	7
268	Critical Human Hepatocyte-Based In Vitro Assays for the Evaluation of Adverse Drug Effects. , 0, , .		0
271	A Review of Herbal Interactions with Warfarin. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2013, 30, 450-470.	0.1	0
273	Development of a Rapid and Cost Effective Assay for the Screening of Reversible Cytochrome P450 Inhibition in Parallel with Cyp3a4 Metabolism-Dependent Inhibition Using Recombinant Proteins. <i>Pharmaceutica Analytica Acta</i> , 2015, 06, .	0.2	0
274	To achieve target international normalized ratio with concurrent warfarin and rifampicin therapy is a challenge: a case report and review of literature. <i>International Journal of Research in Dermatology</i> , 2015, 1, 17.	0.0	0
275	Itching Skin Rash during Valproic Acid Therapy in Co-Administration with Silodosin: a Case Report and Review of Literature. <i>Journal of Clinical & Experimental Dermatology Research</i> , 2016, 07, .	0.1	0
276	Stroke Pharmacogenetics. , 2017, , 327-410.		0
277	The Role of P-Glycoprotein at the Blood-Brain Barrier in Neurological and Psychiatric Disease. , 2021, , 45-81.		0
278	Medications Used for the Respiratory System. , 2020, , 283-317.		0
279	Oxidative Stress in Takotsubo Syndrome—Is It Essential for an Acute Attack? Indirect Evidences Support Multisite Impact Including the Calcium Overload—Energy Failure Hypothesis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 732708.	1.1	8
280	Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4018-4029.	2.9	9
281	Relevant pharmacologic interactions in the concurrent management of brain tumor-related epilepsy and venous thromboembolism: a systematic review. <i>Journal of Neuro-Oncology</i> , 2022, , 1.	1.4	1
282	Machine learning to predict metabolic drug interactions related to cytochrome P450 isozymes. <i>Journal of Cheminformatics</i> , 2022, 14, 23.	2.8	14
284	The Promise of Nanotechnology in Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2022, 12, 673.	1.1	27

#	ARTICLE	IF	CITATIONS
285	Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1239-1247.	0.8	6
286	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	2.1	13
287	Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. <i>Therapeutic Drug Monitoring</i> , 2023, 45, 191-199.	1.0	23
288	Lower buprenorphine elimination rate constant is associated with lower opioid use. <i>Psychopharmacology</i> , 0, , .	1.5	0
289	Inhibitory effect of 20(S)-protopanaxadiol on cytochrome P450: Potential of its pharmacokinetic interactions in vivo. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113514.	2.5	7
290	Managing Covid-19 in patients with heart failure: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 807-828.	0.6	0
291	Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 1127.	1.5	2
292	Metabolites of Cannabigerol Generated by Human Cytochrome P450s Are Bioactive. <i>Biochemistry</i> , 2022, 61, 2398-2408.	1.2	4
293	In vitro effect of <i>Withania somnifera</i> , AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herbâ”drug interactions in the management of COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
294	<i>Atractylodes lancea</i> for cholangiocarcinoma: Modulatory effects on CYP1A2 and CYP3A1 and pharmacokinetics in rats and biodistribution in mice. <i>PLoS ONE</i> , 2022, 17, e0277614.	1.1	2
295	Synthesis and Anticancer Activity of Indole-Functionalized Derivatives of Betulin. <i>Pharmaceutics</i> , 2022, 14, 2372.	2.0	4
296	Design of Cytochrome P450 1B1 Inhibitors <i>via</i> a Scaffold-Hopping Approach. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 398-412.	2.9	3
297	A comparative review of the activity of enzymes of the cytochrome P450 system in humans and laboratory animals. Prognostic value of preclinical models in vivo. <i>Translational Medicine</i> , 2023, 9, 44-77.	0.1	1
298	Medicinal and therapeutic properties of garlic, garlic essential oil, and garlic-based snack food: An updated review. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	16
299	The pharmacogenetics of the new-generation antipsychotics â€” A scoping review focused on patients with severe psychiatric disorders. <i>Frontiers in Psychiatry</i> , 0, 14, .	1.3	5
300	Effects of<i>ABCB1</i>and<i>ABCG2</i>Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18). <i>Anticancer Research</i> , 2023, 43, 1283-1289.	0.5	3
301	Interactions of Betel Quid Constituents with Drug Disposition Pathways: An Overview. <i>Current Drug Metabolism</i> , 2023, 24, .	0.7	0
302	Prevalence of Potential Drug-Drug Interactions Among Hypertensive Pregnant Women Admitted to a Tertiary Care Hospital. <i>Cureus</i> , 2023, , .	0.2	0

#	ARTICLE	IF	CITATIONS
303	Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey. <i>Clinical Therapeutics</i> , 2023, 45, 390-399.e4.	1.1	7